Global Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 2,975.17 Million by 2025, at a CAGR of 10.28% during the assessment period of 2019 to 2025.
Lately, the targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients. The liposome formulations are targeted to reduce the toxicity and surge the accumulation at the target site. This mode of drug delivery lends high efficacy for the administration of various drug classes, such as anti-fungal, anti-viral, antimicrobial, anti-tubercular drugs, vaccines, and gene therapeutics. The increasing occurrences of chronic and life-threatening diseases push the demand for precise drug delivery mechanisms. This pushes the key players to come up with several innovations in the industry to withstand competitive pressure.
The growing understanding of the heterogeneity of patients, the large variety of individual requirements within each given therapy, the rising awareness regarding the importance of a controlled release distribution, and the availability of the drug in the body, are some factors that are positively contributing to the growth of the market.
- The rising number of clinical trials. For instance, Bio-Path Holdings, Inc. has a drug candidate, BP1001, a liposomal Grb2 antisense oligonucleotide, for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that cannot or elect not to be treated with more intensive chemotherapy.
- Growing prevalence of chronic diseases such as cancer and fungal infections. More than 150 million people have serious fungal diseases worldwide, leading to an increasing patient pool. As a result, this leads to the growth of the targeted liposomes drug delivery industry.
- Increased demand for targeted drug delivery
- Increasing adoption of novel therapeutic approaches
- Increased understanding and awareness regarding the drug absorption and metabolism in the body
New product launches in recent years
- Joint ventures of prominent players
- Increasing government funding to support clinical trials
- High investment in research and development by pharmaceutical and biotechnology companies
- Low solubility and short half-life of liposomes can negatively affect the preference rate, hindering the growth of the market
- Liposomal Doxorubicin: Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. This type is used for the treatment of breast cancer, ovarian cancer, and multiple myeloma, among others. The increasing incidence rate of cancers is set to propel the growth of this market.
- Liposomal Paclitaxel: Liposomal Paclitaxel induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances the delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity. The high efficacy rate of this type pushes the demand for the use of this type. This results in the elevation of this segment.
- Liposomal Amphotericin B: Liposomal Amphotericin B is used in the treatment of various fungal and parasitic infections. The increasing fungal infection patient pool is driving the growth of this segment.
- Others: The other segment includes folate targeted liposomes and others.
- Fungal Infection Therapy: Liposomal products, such as Amphoteric and AmBisome is developed for fungal infections. Increasing the prevalence of fungal infections is likely to drive the segment growth in the future.
- Cancer Therapy (Tumor Therapy): Cancer therapy using liposomes uses a targeted liposome drug delivery system. Doxil and Myocet, among others, are injectable polymeric nanoparticle drug formulations that utilize doxorubicin drug for the treatment of cancer.
- Others: Liposomes have become an important carrier system for vaccine development and gene therapeutics, among others.
- Americas: The Americas is estimated to be the largest regional market owing to increasing strategic initiatives, such as mergers, acquisitions, agreements, and joint ventures, employed by major players in the targeted liposomes drug delivery industry. For instance, in February 2020, Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, completed its acquisition of MaSTherCell Global Inc. Such steps promise the growth of the targeted liposomes drug delivery market in the Americas at a substantial rate in the near future.
- Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as increasing awareness created by key players in the market. Also, a lot of key players, such as Lonza (Switzerland), Merck KGaA (Germany), Vetter (Germany), Recipharm AB (Sweden), and Fareva (France), are based in major European countries, which further pushes the growth of the targeted liposomes drug delivery market in this region.
- Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global targeted liposomes drug delivery market. This region is witnessing a surge as major companies are actively involved in expanding their reach by entering into joint ventures, partnerships, collaborations, and agreements. For instance, in November 2019, Recipharm AB (Austria) expanded its Indian injectable dosage form capabilities through a partnership with the Sobti family aimed at creating production capacity in India for a range of sterile dosage forms.
- Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative solutions.
- Catalent (US)
- Pacira Pharmaceuticals, Inc. (US)
- Baxter (US)
- Lonza (Switzerland)
- Evonik (Germany)
- Merck KGaA (Germany)
- Fareva (France)
- Vetter (Germany)
- Polymun Scientific Immunbiologische Forschung GmbH (Austria)
- Recipharm AB (Sweden)
- Dalton Pharma Services (Canada)
USD 2,975.17 Million
Value (USD Million)
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Type and Application
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Catalent (US), Pacira Pharmaceuticals, Inc. (US), Baxter (US), Lonza (Switzerland), Evonik (Germany), Merck KGaA (Germany), Fareva (France), Vetter (Germany), Polymun Scientific Immunbiologische Forschung GmbH (Austria), Recipharm AB (Sweden) and Dalton Pharma Services (Canada)
Key Market Opportunities
The targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients
Key Market Drivers
Increased demand for targeted drug deliveryIncreasing adoption of novel therapeutic approachesGrowing prevalence of chronic diseases such as cancer and fungal infections
Frequently Asked Questions (FAQ) :
Global targeted liposomes drug delivery market is expected to record a substantial market valuation of USD 2.95 billion by 2025.
Global targeted liposomes drug delivery market is projected to register a moderate 10.28% CAGR in the forecast period.
The Liposomal Doxorubicin segment is touted to observe substantial demand over the review period.
The fungal infection therapy segment is slated to mature as the fastest-growing segment.
A few eminent market players functioning in the global targeted liposomes drug delivery market are Baxter (US), Lonza (Switzerland), Evonik (Germany), among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.